Paradigm shift in oncology: targeting the immune system rather than cancer cells

T Shekarian, S Valsesia-Wittmann, C Caux… - …, 2015 - academic.oup.com
The clinical benefits obtained with rituximab in the treatment of CD20+ B-cell malignancies
and of imatinib in the treatment of Phi+ leukaemias have opened a new era in oncology …
被引用次数：65 相关文章

Paradigm shift in oncology: targeting the immune system rather than cancer cells.

T Shekarian, S Valsesia-Wittmann, C Caux… - …, 2015 - search.ebscohost.com
The clinical benefits obtained with rituximab in the treatment of CD20+ B-cell malignancies
and of imatinib in the treatment of Phi+ leukaemias have opened a new era in oncology …

Paradigm shift in oncology: targeting the immune system rather than cancer cells

T Shekarian, S Valsesia-Wittmann, C Caux… - …, 2015 - pubmed.ncbi.nlm.nih.gov
The clinical benefits obtained with rituximab in the treatment of CD20 (+) B-cell malignancies
and of imatinib in the treatment of Phi (+) leukaemias have opened a new era in oncology …

Paradigm shift in oncology: targeting the immune system rather than cancer cells.

T Shekarian, S Valsesia-Wittmann, C Caux… - Mutagenesis, 2015 - europepmc.org
The clinical benefits obtained with rituximab in the treatment of CD20 (+) B-cell malignancies
and of imatinib in the treatment of Phi (+) leukaemias have opened a new era in oncology …
[PDF] archive.org

[PDF][PDF] Paradigm shift in oncology: targeting the immune system rather than cancer cells

T Shekarian, S Valsesia-Wittmann, C Caux… - …, 2015 - scholar.archive.org
The clinical benefits obtained with rituximab in the treatment of CD20+ B-cell malignancies
and of imatinib in the treatment of Phi+ leukaemias have opened a new era in oncology …